

Rui Kong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8033114/publications.pdf>

Version: 2024-02-01

16
papers

2,506
citations

623734

14
h-index

940533

16
g-index

18
all docs

18
docs citations

18
times ranked

2806
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature. <i>Cell Reports</i> , 2020, 32, 107981.	6.4	15
2	Virus-Like Particle Based Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide. <i>Vaccines</i> , 2020, 8, 765.	4.4	12
3	VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage. <i>Cell Host and Microbe</i> , 2020, 27, 531-543.e6.	11.0	23
4	Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen. <i>Scientific Reports</i> , 2020, 10, 3032.	3.3	36
5	Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses. <i>Journal of Virology</i> , 2020, 94, .	3.4	21
6	Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization. <i>Cell</i> , 2019, 178, 567-584.e19.	28.9	106
7	Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting. <i>PLoS ONE</i> , 2019, 14, e0215163.	2.5	41
8	A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope. <i>Immunity</i> , 2018, 48, 500-513.e6.	14.3	66
9	Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. <i>Nature Medicine</i> , 2018, 24, 857-867.	30.7	256
10	Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. <i>PLoS Pathogens</i> , 2017, 13, e1006148.	4.7	51
11	Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. <i>PLoS Pathogens</i> , 2016, 12, e1005520.	4.7	150
12	Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. <i>Science</i> , 2016, 352, 828-833.	12.6	310
13	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. <i>Cell</i> , 2016, 165, 449-463.	28.9	305
14	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. <i>Cell</i> , 2015, 161, 1280-1292.	28.9	305
15	Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes. <i>Journal of Virology</i> , 2015, 89, 2659-2671.	3.4	123
16	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. <i>Nature</i> , 2014, 509, 55-62.	27.8	681